2
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Conditions
Skin Diseases, Papulosquamous
1
Skin Diseases
1
Sarcoma, Synovial
1
Sarcoma
1
Psoriasis
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Plaque, Amyloid
1
Myelodysplastic Syndromes
1
Lymphoma, Follicular
1
Lymphoma
1
Liposarcoma, Myxoid
1
Leukemia, Myeloid, Acute
1
Leukemia, Biphenotypic, Acute
1
Leiomyosarcoma
1
Histiocytoma, Malignant Fibrous
1
Graft vs Host Disease
1
Chondrosarcoma
1
Bronchiolitis Obliterans Syndrome
1
Arthritis, Rheumatoid
1
Adenoma, Liver Cell
1
Interventions
Adalimumab
19
Etanercept
16
Methotrexate
11
Infliximab
8
tocilizumab
7
Rituximab
7
golimumab
6
Abatacept
6
tofacitinib
5
Tumor Necrosis Factor Inhibitors
5
olokizumab
4
Certolizumab Pegol
4
Antirheumatic Agents
3
Saline Solution
2
RC-18
2
Nivolumab
2
Leflunomide
2
veltuzumab
1
upadacitinib
1
secukinumab
1
sarilumab
1
mavrilimumab
1
entecavir
1
cabozantinib
1
baricitinib
1
andecaliximab
1
Vitamin D
1
Vaccines
1
TACI receptor-IgG Fc fragment fusion protein
1
Syringes
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Arthritis, Rheumatoid
×
baricitinib
×
Clear all
NCT01721044
2019-09-18
RA-BEACON
Eli Lilly and Company
Phase 3
Completed
527 enrolled
37 charts